<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>With the advent of Highly-Active-Anti-Retroviral-Therapy (HAART), HIV patients can expect to live beyond 10-15 years following diagnosis </plain></SENT>
<SENT sid="1" pm="."><plain>An unexpected result of increased survival is the emergence of opportunistic, oncogenic virus-associated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> such as Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (Epstein-Barr Virus), <z:e sem="disease" ids="C0302592" disease_type="Neoplastic Process" abbrv="">cervical cancer</z:e> (Human <z:mpath ids='MPATH_445'>Papilloma</z:mpath> Virus) and <z:hpo ids='HP_0100726'>Kaposi's sarcoma</z:hpo> (<z:hpo ids='HP_0100726'>Kaposi's sarcoma</z:hpo>-associated herpesvirus) in this immuno-compromised population </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, there are reports of <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) in long-term HIV-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> survivors </plain></SENT>
<SENT sid="3" pm="."><plain>Compared to the general, non-immuno-compromised population, long-term <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> patients have 4 and 3.3-fold increased risk of developing colorectal and anorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Unlike oncogenic virus-associated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> is not known to have a <z:mp ids='MP_0001799'>viral</z:mp> etiology </plain></SENT>
<SENT sid="5" pm="."><plain>Our study aimed to investigate one aspect of <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e> and colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>We proposed that the HIV transactivator protein Tat; a protein with known oncogenic properties that is secreted and can re-enter non-infected cells may have a role in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Using two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines, LIM1215 and LIM2537 we found that Tat inhibits epithelial cyto-differentiation, blocks <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in vitro and accelerates <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> formation in vivo </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, Tat significantly increases in vitro migration in the absence of foetal calf serum </plain></SENT>
<SENT sid="9" pm="."><plain>These properties underpin <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, and as <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e> is initiated in the gut lymphoid system, these data provide a basis for the increased incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> in long term <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> patients </plain></SENT>
</text></document>